Boehringer Ingelheim Primes For Top Five Multinational Slot In India

Global Pipeline, Diabetes Key

Boehringer Ingelheim’s incoming India managing director outlines intent to scale up in areas including diabetes and stroke, as the private German multinational seeks to move up the rankings in the competitive Indian market. Enabling the global pipeline in field including immunology, CNS and oncology also part of the effort.

Arrows up (Monster Ztudio/Shutterstock.com)
BI Aims To Sustain Scorching Growth In India • Source: Shutterstock

Boehringer Ingelheim GmbH's new India chief, Vani Manja, has outlined a roadmap to sustain the “remarkable” pace of growth the private German company has seen on the local market,, and hopes to steer the firm into the top five position among multinationals in the country over the next few years.

Manja, BI India’s first woman country managing director, outlined at a media roundtable a range of priority areas in 2021 to move up the ranks among foreign firms, including building on the company’s strong position in the diabetes segment by developing “holistic care models”,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia